SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JohnBeach who wrote (53449)12/15/2019 8:44:11 AM
From: CPark6 Recommendations

Recommended By
bobbseytwins2001
CelebrityEquity
EMU2
idahoranch1
patlawche11

and 1 more member

   of 63291
 
"They are different compounds, but with the same ILD problem. It suggests that there is an issue with the ADC construct."

This has to be the most probable conclusion, and this is the most ideal outcome for SG. The studies are showing targeting Trop-2 is quite effective, not only by SG, but other Trop-2 ADCs as well. But, other Trop-2 ADCs are showing quite unfavorable safety profiles, most likely due to their ADC construct design. This leaves SG in monopoly position in Trop-2 targeting ADC market. With the combo therapies becoming more and more the norm, SG seems to have quite a bright future.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News